
Hedge Funds Meet With Companies
This is a little bit fanciful, but not that fanciful. CEOs do regularly meet with investors, and the investors ask questions and the CEOs answer them. In the US, securities regulations prohibit the CEOs from disclosing material nonpublic information in these meetings, so in theory, if you ask the CEO about next quarter's earnings, she shouldn't tell you anything the company hasn't already said publicly. In practice, though, these meetings do happen, which suggests that investors get some value out of them. And empirical studies find that, as you'd expect, investors who have meetings with CEOs make more informed investing decisions. They're definitely learning something in the meetings.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
21 minutes ago
- Bloomberg
Confusion Over Tariff Stacking Hampers Japan's Bid to Pin Down US Trade Deal
A fresh discrepancy in interpretations of the US-Japan trade deal came to the fore on Thursday, as Japan's chief negotiator visits Washington to press for follow-through on a pledge to cut a levy on car imports to 15%. Japanese media reports said Washington would not exempt Tokyo from an order stacking new 15% across-the board tariffs on top of existing levies, hours before they come into effect. Japan's top trade negotiator Ryosei Akazawa said Tuesday that levies would not be stacked on top.
Yahoo
23 minutes ago
- Yahoo
Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment?
Strong Q2 results have led to a further uproar in Axon Enterprise AXON and Palantir Technologies PLTR shares this week, remaining two of the hottest momentum stocks. Axon's stock has now spiked over +40% year to date, with Palantir shares surging more than +130%. More astonishing, AXON is up over +640% in the last three years with PLTR skyrocketing more than 1,700%. Considering their millionaire-maker-like gains, investors are surely wondering which of these hot stocks is the better investment at the moment. Image Source: Zacks Investment Research Axon Thrives on Increased Public Safety Spending Thanks to increased global defense and public safety spending, Axon easily surpassed its Q2 expectations while posting stellar top and bottom line growth. The innovative manufacturer of weapons for the U.S. and international governments posted Q2 sales of $668.54 million, which soared nearly 33% year over year and comfortably topped estimates of $642.98 billion by 4%. Furthermore, this marked the 14th consecutive quarter of revenue growth above 25%, with CEO Rick Smith stating Axon is seeing broad demand across the company's portfolio, including for its AI services, drones, cameras, and virtual reality solutions. More impressive, Axon's Q2 earnings came in at $2.12 per share, crushing expectations of $1.54 by 37% and soaring 76% from $1.20 in the prior period. Axon has now exceeded the Zacks EPS Consensus for a remarkable 33 consecutive quarters, with a very impressive average earnings surprise of 25.87% in its last four quarterly reports. Image Source: Zacks Investment Research Palantir's First Billion-Dollar Quarter Also thriving from increased defense spending, including the securement of a $10 billion contract with the U.S. Army, Palantir achieved its first-ever billion-dollar quarter, topping estimates of $938.33 million. This was a 48% spike from Q2 sales of $678.13 million a year ago, as the software provider saw strong demand for its artificial intelligence platform (AIP) outside of the intelligence communities. Pinpointing increased commercial demand for AIP, Palantir CEO Alex Karp stated that companies are using Palantir's tools not just to optimize operations, but to reshape entire business models. Palantir is also taking advantage of its expansive sales growth, with Q2 EPS of $0.16 rising from $0.09 a share in the comparative quarter and edging expectations of $0.14. Notably, Palantir has now reached of exceeded the Zacks EPS Consensus for 11 consecutive quarters with an average earnings surprise of 13.17% over the last four quarters. Image Source: Zacks Investment Research Axon & Palantir Raise Their Full-Year Guidance Adding fuel to investor sentiment is that Axon and Palantir have raised their full-year revenue guidance. Optimistically, Axon now forecasts fiscal 2025 revenue at $2.65-$2.73 billion, up from $2.6-$2.7 billion. It's also noteworthy that Axon expects full-year adjusted EBITDA of $665-$685 million, raised from $650-$675 million. Pivoting to Palantir, the company raised its FY25 revenue forecast to $4.142 billion-$4.15 billion, up from previous guidance of $3.89 billion-$3.9 billion. The bump is specifically attributed to full-year commercial revenue guidance increasing to over $1 billion, reflecting at least 85% growth. Additionally, Palantir raised its adjusted income from operations guidance to between $1.912 billion-1.92 billion and increased its adjusted free cash flow guidance to $1.8 billion-$2 billion. Monitoring Axon & Palantir's Valuation While Axon is well ahead in terms of moving further past the probability line than Palantir, the price-to-sales ratio may still be a better indicator of judging the value these hot stocks offer to investors at their current levels, rather than price-to-earnings. That said, Axon is also growing into its lofty valuation more swiftly regarding the P/S ratio after a rebranding to reflect its broader mission in public safety technology. To that point, Axon trades at 25X forward sales, which is far more reasonable than Palantir's 104X. Image Source: Zacks Investment Research Conclusion & Final Thoughts Although Palantir's ability to benefit from the AI boom makes it the better momentum stock at the moment, Axon appears to be the overall better investment when considering its more justifiable valuation. Axon's profitability also makes it a more sound investment, and earnings estimate revisions (EPS) have remained higher, correlating with AXON sporting a Zacks Rank #1 (Strong Buy). On the other hand, Palantir stock lands a Zacks Rank #3 (Hold), and investors may certainly be looking for better entry points given PLTR doesn't offer much fundamental value after such a monstrous year-to-date rally. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Palantir Technologies Inc. (PLTR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) reported $611.09 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 68.4%. EPS of $2.02 for the same period compares to $0.07 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $529.54 million, representing a surprise of +15.4%. The company delivered an EPS surprise of +81.98%, with the consensus EPS estimate being $1.11. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product, net: $513.12 million versus $506.99 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +42.3% change. Revenues- PMO Products: $231.27 million versus the seven-analyst average estimate of $228.28 million. Revenues- Collaboration: $97.97 million compared to the $21.79 million average estimate based on seven analysts. The reported number represents a change of +4011.1% year over year. Revenues- Product, net- ELEVIDYS: $281.85 million versus the seven-analyst average estimate of $277.86 million. The reported number represents a year-over-year change of +131.6%. View all Key Company Metrics for Sarepta Therapeutics here>>> Shares of Sarepta Therapeutics have returned -12% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research